Lytix Biopharma

Description

Lytix Biopharma develops the ruxotemitide (LTX-315) oncolytic molecule program, building intratumoral peptide-based therapies that lyse cancer cell membranes and induce abscopal anti-tumor immune responses for neoadjuvant treatment of solid tumors.

Lytix Biopharma is located in the Oslo ecosystem.

Related

• 21st.BIO A/SBuilds a precision fermentation technology platform providing strains, fermentation processes, and downstream workflows for…
• 3D Systems ($DDD)3D Systems provides 3D printers, materials, software and services for industrial manufacturing, healthcare, dental, jewelry, aerospace,…
• AbbelightAbbelight provides workflow solutions for biological imaging, sample preparation, and data analysis.
• Ability PharmaceuticalsAbilityPharma develops biopharmaceutical drug candidates. Its clinical pipeline targets cancer treatment, including ABTL0812 trials for…
• AbInitio BioAbInitio Bio builds an AI-native operating platform for drug development and manufacturing, helping teams assess developability, accelerate…
• AbridgeAbridge builds an AI assistant that turns clinical conversations into draft and billable documentation for clinicians, nursing teams, and…
• ACD PharmaACD Pharma develops bacteriophage-based biocontrol products and technologies for preventing and treating bacterial infections with…
• ACIES BIO d.o.o.Builds end-to-end solutions in microbial biotech for industrial customers needing strain development, bioprocess scale-up, downstream…
• ActitheraActithera develops targeted radioligand therapies by linking radioactive isotopes to designed molecules for delivery of radiation to…